A biosimilar of infliximab, CT-P13, has equivalent safety and efficacy to that of the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn's disease in infliximab-naïve patients. Findings from a comparative ...
Dec 11, 2018
0
1
(HealthDay)—For patients with acute severe ulcerative colitis (ASUC), the baseline Mayo Endoscopic Score and the C-reactive protein (CRP)/albumin ratio predict treatment response to infliximab, according to research published ...
Jan 3, 2018
0
1
Biosimilars are biologic agents that highly similar to original biomedical medications (originators), but are much cheaper. A new study in Alimentary Pharmacology & Therapeutics found no differences in drug levels and disease ...
Dec 6, 2017
0
0
In patients with inflammatory bowel disease (IBD), the body attacks the lining of the digestive tract. Up to half of patients who benefit from the first-line anti-inflammatory drug infliximab eventually stop responding to ...
Oct 3, 2017
0
0
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react ...
Jun 9, 2016
0
1
(HealthDay)—For patients with inflammatory bowel disease (IBD), infliximab and/or azathioprine treatment is associated with poor response rate to hepatitis B virus (HBV) vaccination, according to a study published in the ...
Oct 21, 2015
0
9
(HealthDay)—For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, according to a study published ...
Sep 2, 2015
0
16
(HealthDay)—For patients with moderate to severely active ulcerative colitis (UC), clinical nonresponders to infliximab have high concentrations of infliximab in fecal samples, according to a study published in the August ...
Aug 5, 2015
0
31
Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient's chances of having a long-term successful response to therapy, a pilot ...
Sep 11, 2014
0
0
Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice ...
Sep 5, 2014
0
0
